Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Tela Bio, Inc.

NASDAQ: TELA · Industrial Applications and Services · 9 alerts · CIK 1561921

Share price
$0.7616Close, Nov 16
Market cap
$34.4M
Shares outstanding
45.19MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Tela Bio, Inc. filings on SEC EDGAR ↗

4:16 PM ET 10-Q
Financial Results

Tela Bio Q3 2026 Results: Net Loss of $9.3M, Loss Widens

TELA Bio reported a net loss of $32.8 million for the nine months ended September 30, 2026, as revenue declined slightly to $57.3 million from $59.4 million in the prior year. A significant balance sheet shift occurred as $56.3 million in debt was reclassified to current liabilities, contributing to a total stockholders' deficit of $24.6 million.

Key figure
Net loss $9.3M
4:05 PM ET 8-K
Financial Results

Tela Bio Financial Results

TELA Bio reported Q3 2026 revenue of $19.0 million, an 8% decrease year-over-year primarily due to lower OviTex PRS volumes. The company implemented a strategic cost reduction initiative to reduce annual operating expenses by $17.0 million and extend its cash runway into 2028. During the quarter, the company also regained Nasdaq compliance and received 510(k) clearance for its Liora Monofilament Scaffold.

Term
Q3 2026

“My first quarter as CEO was focused on putting a plan in place to return TELA Bio to growth. I joined because I believe OviTex is best-in-class technology and that we are well positioned to win in an evolving soft tissue repair and reconstruction market.”

Heather Getz, Chief Executive Officer of TELA Bio

“Our cost reduction initiative allows us to thoughtfully reallocate resources, supports a return to topline growth, and extends our cash runway. In the third quarter alone, we reduced our adjusted EBITDA loss by 55% versus the second quarter of 2026 while delivering sequential revenue growth in the US hernia market and continued year-over-year growth in Europe.”

Heather Getz, Chief Executive Officer of TELA Bio

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.